George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Yes you were quite right - price looks good- what will Mr Market make of it though? Its not all cash and mo returns offered to us long term suffering shareholders. We will see but move makes total sense.
A mixed bag is the answer. Obviously a lot of lazy money follows him so as you have seen today with GATC this chases the price and the MM are only too happy to see the action. ST pushes so may shares its bound to be a mixed bag. He is tasked by IC to unearth hidden value but the market already does that! One of his long term absolutely cast iron recommends was for INL - year after year and in the past two few its gone from 80p to sub 20. I am not saying he does not get some right and he is careful to show YoY that he beats the market. But as with all investing it pays to do your own research. Also remember that if you do want to buy a recommended share, wait a bit, the froth often comes off in the subsequent days and weeks.
BRIEF-MGC Pharmaceuticals Seeks Trading Halt
MGC PharmaceuticalsMGC Pharmaceuticals
News
1:01 am
Oct 24 - MGC Pharmaceuticals Ltd MXC.AX :
* SEEKS TRADING HALT PENDING ANNOUNCEMENT ON STATISTICAL
ANALYSIS
OF RESULTS FROM A RECENT CLINICAL TRIAL
Source text for Eikon: ID:nASX8nZnz7
Further company coverage: MXC.AX
((Reuters.Briefs@thomsonreuters.com;))
The dangers in the region https://www.bbc.co.uk/news/world-africa-61207441
Drug ready for cancer test
Scancell Holdings shares hit a two-month high yesterday after the drugs maker said it was recruiting patients to test its cancer treatment on.
It will be the first clinical trial for the drug Modi-1 on humans. It will assess Modi-1 in four cancer types, including triple-negative breast, ovarian, head and neck, and renal.
Scancell’s Modi-1 will be assessed against four cancer types
Scancell’s Modi-1 will be assessed against four cancer types
The Nottingham-based group said oncology research sites and investigators across the UK have agreed to contribute patients to the study, with the first wave of clinical sites open for recruitment. Scancell expects up to 20 sites to be recruiting.
The UK’s Medicines and Healthcare products Regulatory Agency approved a study protocol modification that should speed recruitment as well as shorten the study’s overall timeline.
Lindy Durrant, Scancell’s chief executive, said recruitment marked a “major step forward”.
“We are very excited about the prospects for Modi-1 based on the dramatic regression of large tumours in our preclinical models and look forward to accelerating recruitment and analysing early safety and immunogenicity data later this year.”
The shares rose 6¼p, or 57.2 per cent, to close at 17p.
I’ve been in Tern for around 4 months now having bought first at 16 then in batches up 29 (fool) and of course I have seen the subsequent fall. The rise yesterday is welcome and of course I too dream of a rerating around an event. But isn’t the point that this share is manipulated by traders- aided and abetted by rampers. It suits this community and indeed those over on ADVFN that it yo-yos. Until Tern pulls a rabbit out of hat I suspect we will see the cycle repeated. Just saying. And no I do not trade!
Paul Scott has written a very balanced and positive piece in the last hour. I won’t cut and paste it but subscribers can benefit from his careful and considered analysis (which is worth more than almost any other source). Boiled down he acknowledges the very good progress of the board. I hold.
I too am thinking that despite bullish trading update that there is some bad news awaiting us holders on Monday. When will I learn to put stop losses in place even when a share goes up and I'm in good profits? This has dropped almost a £ now in a few weeks. I must do better.